Boston Scientific Corporation BSX | NYSE
Company Overview:
10 Year Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
BSX Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for BSX
Based on past 10-year performance, here are BSX growth metrics:
Share price CAGR of +19.25%
Dividend CAGR of +0%
Using BSX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| BSX (DRIP) | BSX - No DRIP | |
|---|---|---|
| Current Price | $103.19 | $103.19 |
| Start Shares | 96.91 | 96.91 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 96.91 | 96.91 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $503.33 | $103.19 |
| Total Dividends | $0 | $0 |
| Final Value | $48,777 | $10,000 |
NOTE: Above numbers are our estimate based on BSX's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
Boston Scientific Corporation (BSX) had its IPO on 1992-05-19, and is trader on NYSE stock exchange.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
BSX website: https://www.bostonscientific.com
